You are here

  • Home
  • Archive
  • Volume 6, Issue Suppl 1
  • 98 Results of a phase 2, double-blind, randomized, placebo-controlled study of a reversible B cell inhibitor, XmAb®5871, in systemic lupus erythematosus (SLE)

Article metrics

Article menu

Download PDFPDF

Abstracts
98 Results of a phase 2, double-blind, randomized, placebo-controlled study of a reversible B cell inhibitor, XmAb®5871, in systemic lupus erythematosus (SLE)
Free

 

Online download statistics by month:

Online download statistics by month: April 2019 to September 2024

AbstractFullPdf
Apr 201924013
May 20193008
Jun 20191203
Jul 20193406
Aug 20191606
Sep 20191807
Oct 20191406
Nov 20191304
Dec 20192802
Jan 20206903
Feb 20206700
Mar 20206408
Apr 20206105
May 20206702
Jun 202068040
Jul 20207804
Aug 20206801
Sep 20207601
Oct 2020101016
Nov 20206103
Dec 20208401
Jan 20215105
Feb 20211005
Mar 20212007
Apr 20211504
May 2021102
Jun 2021301
Jul 2021108
Aug 2021005
Sep 2021003
Oct 202114021
Nov 20211609
Dec 20211003
Jan 20221205
Feb 2022801
Mar 20221304
Apr 20221104
May 202216010
Jun 2022603
Jul 20223605
Aug 20222402
Sep 202235011
Oct 20221003
Nov 20222305
Dec 20223802
Jan 20232402
Feb 20232202
Mar 202345012
Apr 20231008
May 2023200
Jun 20231203
Jul 20232008
Aug 20233807
Sep 20232701
Oct 20231804
Nov 20232306
Dec 20231806
Jan 20241602
Feb 20242007
Mar 20242609
Apr 20242405
May 20242102
Jun 20241805
Jul 202422015
Aug 20242408
Sep 20241406
Total18700385